[go: up one dir, main page]

DE60129254D1 - Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b - Google Patents

Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b

Info

Publication number
DE60129254D1
DE60129254D1 DE60129254T DE60129254T DE60129254D1 DE 60129254 D1 DE60129254 D1 DE 60129254D1 DE 60129254 T DE60129254 T DE 60129254T DE 60129254 T DE60129254 T DE 60129254T DE 60129254 D1 DE60129254 D1 DE 60129254D1
Authority
DE
Germany
Prior art keywords
rank
kappa
agonists
antagonists
screening process
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129254T
Other languages
English (en)
Other versions
DE60129254T2 (de
Inventor
William C Dougall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE60129254D1 publication Critical patent/DE60129254D1/de
Publication of DE60129254T2 publication Critical patent/DE60129254T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60129254T 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b Expired - Lifetime DE60129254T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23515700P 2000-09-22 2000-09-22
US235157P 2000-09-22
PCT/US2001/029857 WO2002024896A2 (en) 2000-09-22 2001-09-20 Screening assays for agonists or antagonists of receptor activat or of nf-kb

Publications (2)

Publication Number Publication Date
DE60129254D1 true DE60129254D1 (de) 2007-08-16
DE60129254T2 DE60129254T2 (de) 2008-03-13

Family

ID=22884325

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0001368464T Pending DE01973455T1 (de) 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
DE60129254T Expired - Lifetime DE60129254T2 (de) 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE0001368464T Pending DE01973455T1 (de) 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b

Country Status (10)

Country Link
US (2) US6884598B2 (de)
EP (1) EP1368464B1 (de)
JP (1) JP4854174B2 (de)
AT (1) ATE366306T1 (de)
AU (2) AU9303001A (de)
CA (1) CA2423052C (de)
DE (2) DE01973455T1 (de)
ES (1) ES2208145T3 (de)
MX (1) MXPA03002443A (de)
WO (1) WO2002024896A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CN1264427A (zh) * 1997-04-16 2000-08-23 安姆根有限公司 osteoprotegerin结合蛋白和受体
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002092016A2 (en) * 2001-05-17 2002-11-21 Immunex Corporation Therapeutic use of rank antagonists
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
CA2463478A1 (en) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methods for screening osteogenic compounds
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2004029620A2 (en) * 2002-09-26 2004-04-08 Novartis Ag Screening method involving transfected primary t cells
WO2005020924A2 (en) * 2003-08-29 2005-03-10 Centocor, Inc. A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
US8853367B1 (en) 2004-09-15 2014-10-07 The Uab Research Foundation Compositions and methods for modulating rank activities
PE20070684A1 (es) * 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
CN101313251A (zh) * 2005-11-23 2008-11-26 纳幕尔杜邦公司 再循环烷烃浸渍液的装置及使用方法
WO2010129710A1 (en) * 2009-05-06 2010-11-11 Emory University Use of rankl to induce differentiation of microfold cells (m cells)
US8598331B2 (en) * 2009-09-28 2013-12-03 The University Of British Columbia CLDN5 mini-promoters
JP5867671B2 (ja) * 2011-03-28 2016-02-24 国立大学法人神戸大学 コンディショナルノックアウト動物
US9757451B2 (en) 2011-11-07 2017-09-12 UNIVERSITé LAVAL Use of RANK/RANKL antagonists for treating muscular dystrophy
US10253330B2 (en) 2013-02-13 2019-04-09 The University Of British Columbia CLDN5 mini-promoters

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127637A (en) * 1872-06-04 Improvement in couplings for divided axles
US133170A (en) * 1872-11-19 Improvement in wheelbarrows
US13651A (en) * 1855-10-09 Machine for making wire dish-covers
US159970A (en) * 1875-02-16 Improvement in sickle-heads for harvesters
US68690A (en) * 1867-09-10 bibge
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
GB9310194D0 (en) * 1993-05-18 1993-06-30 Millenium Bioligix Inc Assessment of osteoclast activity
JPH0956805A (ja) * 1995-08-24 1997-03-04 Millennium Biologics Inc リン酸カルシウム材の薄膜製造のための改良焼結方法
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
JP2001506991A (ja) 1996-12-13 2001-05-29 シェーリング コーポレイション Ｔｎｆリガンドファミリーのメンバーに特徴的な構造的モチーフを含む哺乳動物細胞表面抗原
DE122010000048I1 (de) * 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
EP1657255B1 (de) 1997-04-15 2014-07-30 Sankyo Company, Limited Neues Protein und Methode um dieses Protein herzustellen
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CN1264427A (zh) 1997-04-16 2000-08-23 安姆根有限公司 osteoprotegerin结合蛋白和受体
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
JPH119269A (ja) 1997-06-19 1999-01-19 Kaken Pharmaceut Co Ltd 破骨細胞系細胞
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
EP1114166B1 (de) 1998-09-15 2005-03-23 Pharmexa A/S Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
AU5379200A (en) 1999-06-02 2000-12-28 Osteopharm Inc. Bone stimulating factor
US6492124B1 (en) * 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
WO2001008677A1 (en) 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
JP2003505514A (ja) 1999-07-28 2003-02-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞生成を阻害する方法
AU6946300A (en) 1999-08-30 2001-03-26 Mayo Foundation For Medical Education And Research Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
HUP0104688A3 (en) 1999-09-03 2004-07-28 Amgen Inc Thousand Oaks Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
EP1087230A1 (de) 1999-09-24 2001-03-28 Boehringer Ingelheim International GmbH Verfahren zum Nachweis von Verbindungen nützlich in Therapie von Knochenfehlern
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
DK2105449T3 (da) 2000-02-23 2019-10-07 Amgen Inc Antagonistiske selektive bindemidler af osteoprotegerinbindende protein
WO2001091793A1 (en) 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002016551A2 (en) 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
US20030211106A1 (en) 2000-08-21 2003-11-13 Tornetta Mark A Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002064782A2 (en) 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
CA2441538A1 (en) 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
US20030013651A1 (en) 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
IL157614A0 (en) 2001-03-23 2004-03-28 Genentech Inc Uses of opg ligand to modulate immune responses
NZ529314A (en) 2001-05-11 2007-01-26 Res Dev Foundation Inhibitors of receptor activator of NF-kappaB and uses thereof
WO2002095012A1 (en) 2001-05-18 2002-11-28 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl

Also Published As

Publication number Publication date
DE60129254T2 (de) 2008-03-13
ATE366306T1 (de) 2007-07-15
DE01973455T1 (de) 2004-04-22
CA2423052A1 (en) 2002-03-28
AU9303001A (en) 2002-04-02
US20050196801A1 (en) 2005-09-08
AU2001293030B2 (en) 2007-07-19
EP1368464B1 (de) 2007-07-04
ES2208145T3 (es) 2007-12-16
US20020086312A1 (en) 2002-07-04
WO2002024896A9 (en) 2002-10-03
WO2002024896A2 (en) 2002-03-28
US7572594B2 (en) 2009-08-11
ES2208145T1 (es) 2004-06-16
JP2004524812A (ja) 2004-08-19
JP4854174B2 (ja) 2012-01-18
EP1368464A2 (de) 2003-12-10
CA2423052C (en) 2011-07-12
US6884598B2 (en) 2005-04-26
MXPA03002443A (es) 2004-12-06
WO2002024896A3 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
DE60129254D1 (de) Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
Selkirk et al. SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity
Nishimura et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression
Riggi et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells
Brixius et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium
Uhlén et al. [3H] RS79948-197 binding to human, rat, guinea pig and pig α2A-, α2B-and α2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine
Saussy et al. Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype.
ATE144773T1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE60127656D1 (de) Integrin antagonisten
MXPA04001287A (es) Ensayo de receptor unido a proteina g.
Mahé et al. Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors
Haber et al. Inhibitors of renin and their utility in physiologic studies.
ATE132162T1 (de) Humane gammainterferonantagonisten
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
Pregenzer et al. Characterization of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors
Silva et al. Expression and pharmacological characterization of α1-adrenoceptors in rat seminal vesicle
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
Wainscott et al. Human 5-HT1F receptor-stimulated [35S] GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation
DE69333660D1 (de) Pct-65 serotonin rezeptor
Nanda et al. Vinculin regulates assembly of talin: β3 integrin complexes
DE60038902D1 (de) Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
DE60130565D1 (de) Pde8a und seine verwendung
Kaplan et al. Combined defect in membrane expression and activation of platelet GPIIb–IIIa complex without primary sequence abnormalities in myeloproliferative disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition